Therapeutic patenting for glucocorticoid-induced osteoporosis

Bibliography

• EASTELL R: Management of corticosteroid-inducedosteoporosis. J. Intern. Med. (1995) 237:439–447.
   PubMed Web of Science ®Google Scholar
• CANALIS E: Clinical review 83. Mechanisms ofglucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. (1996) 81:3441–3447.
   Google Scholar
• Consensus development conference, prophylaxis andtreatment of osteoporosis. Am. J. Med. (1991) 90:107–110.
   PubMedGoogle Scholar
• MANOLAGAS SC, WEINSTEIN RS: New developments inthe pathogenesis and treatment of steroid-induced osteoporosis. J. Bone Miner. Res. (1999) 14:1061–1066.
   PubMed Web of Science ®Google Scholar
• •Review of the potential importance of osteoblast numbers for bone integrity.
   Google Scholar
• KING CS, WEIR EC, GUNBERG CW, FOX J, INSOGNA KL:Effects of continuous glucocorticoid infusion on bone metabolism in the rat. CaRif Tissue Int. (1996) 59:184–191.
   PubMed Web of Science ®Google Scholar
• DEMPSTER DW, MOONGA BS, STEIN LS, HORBERT WR,ANTAKLY T: Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J. Endocrinol (1997) 154:397–406.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN RS, JILKA RL, PARFITT AM, MANOLAGAS SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorti-coids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. (1998) 102:274–282.
   PubMed Web of Science ®Google Scholar
• ••Proposed pathological basis of GIOP and description of amurine model of GIOP.
   Google Scholar
• ADACHI JD, BENSEN WG, BROWN J et al: Intermittent therapy to prevent corticosteroid-induced. N Engl. J. Med. (1997) 337:382–387.
   PubMed Web of Science ®Google Scholar
• •First randomised controlled trial of a bisphosphonate in GIOP.
   Google Scholar
• SAAG KG, EMKEY R, SCHNITZER TJ et al: Alendronate the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl. J. Med. (1998) 339:292–299.
   PubMed Web of Science ®Google Scholar
• •Randomised controlled trial of an aminobisphosphonate in GIOP.
   Google Scholar
• COHEN S, LEVY RM, KELLER M et al: Risedronatetherapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. (1999) 42:2309–2318.
   PubMed Web of Science ®Google Scholar
• VAN BEEK E, PIETERMAN E, COHEN L, LOWIK C, PAPAPOULOS S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphos-phonates. Biochem. Biophys. Res. Commun. (1999) 264:108–111.
   PubMed Web of Science ®Google Scholar
• BERGSTROM JD, BOSTEDOR RG, MASARACHIA PJ, RESZKA AA, RODAN G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. (2000) 373:231–241.
   PubMed Web of Science ®Google Scholar
• DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitisassociated with the use of alendronate. N Engl. J. Med. (1996) 335:1016–1021.
   PubMed Web of Science ®Google Scholar
• PETER CP, HANDT LK, SMITH SM: Esophageal irritationdue to alendronate sodium tablets: possible mechanisms. Dig. Dis. Sci. (1998) 43:1998–2002.
   PubMed Web of Science ®Google Scholar
• PLOTKIN LI, WEINSTEIN RS, PARFITT AM, ROBERTSON, MANOLAGAS SC, BELLIDO T: Prevention of osteocyte and osteoblast apoptosis by bisphosphon-ates and calcitonin. j Clin. Invest. (1999) 104:1363–1374.
   PubMed Web of Science ®Google Scholar
• •Description of a possible mechanism for anabolic effects of bisphosphonates.
   Google Scholar
• GOHEL A, MCCARTHY MB, GRONOWICZ G: Estrogenprevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology (1999) 140:5339–5347.
   PubMed Web of Science ®Google Scholar
• LOVE RR, MAZESS RB, BARDEN HS et al.: Effects oftamoxifen on bone mineral density in postmeno-pausal women with breast cancer. N Engl. J. Med. (1992) 326:852–856.
   PubMed Web of Science ®Google Scholar
• SAMBROOK P, BIRMINGHAM J, KEMPLER S, NGUYEN T,POCOCK N, ELSMAN J: Prevention of corticosteroid osteoporosis - a comparison of calcium, calcitriol and calcitonin. N Engl. J. Med. (1993) 328:1747–1752.
   PubMed Web of Science ®Google Scholar
• LACEY DL, TIMMS E, TAN H-L et al.: Osteoprotegerin(OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 93:165–176.
   PubMed Web of Science ®Google Scholar
• •First description of OPG.
   Google Scholar
• YASUDA H, SHIMA N, NAKAGAWA N et al.: Osteoclast factor is a ligand for osteoprote-gerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. (1998) 95:3597–3602.
   PubMed Web of Science ®Google Scholar
• •Original description of RANKL (along with reference below).
   Google Scholar
• FULLER K, WONG B, FOX S, CHOI Y, CHAMBERS TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med (1998) 188:997–1001.
   PubMed Web of Science ®Google Scholar
• •Original description of RANKL (along with reference above).
   Google Scholar
• HOFBAUER LC, GORI F, RIGGS BL et al.: Stimulation of ligand and inhibition of osteoprote-gerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 140:4382–4389.
   PubMed Web of Science ®Google Scholar
• •Changes in osteoblastic OPG and RANKL expression with glucocorticoids in vitro.
   Google Scholar
• KONG YY, FEIGE U, SAROSI I et al.: Activated T cellsregulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 402:304–309.
   PubMed Web of Science ®Google Scholar
• FINKELSTEIN JS, KLIBANSKI A, ARNOLD AL, TOTH TL,HORNSTEIN MD, NEER RM: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA (1998) 280:1067–1073.
   PubMed Web of Science ®Google Scholar
• JILKA RL, WEINSTEIN RS, BELLIDO T, ROBERSON P,PARFITT AM, MANOLAGAS SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. (1999) 104:439–446.
   PubMed Web of Science ®Google Scholar
• •Potential novel mechanism of action of PTH.
   Google Scholar
• LANE NE, SANCHEZ S, MODIN GW, GENANT HK, INI E, CD: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. (1998) 102:1627–1633.
   Google Scholar
• ••Important study demonstrating efficacy of PTH in GIOP.
   Google Scholar
• MORLEY P, WHITFIELD JF, WILLICK G: Parathyroid analogues for treatment of osteoporosis and hypercalcaemia. Exp. Opin. Ther. Patents (1998) 8:31–37.
   Web of Science ®Google Scholar
• OHLSSON C, BENGTSSON BA, ISAKSSON OG, ANDREASSEN TT, SLOOTWEG MC: Growth hormone and bone. Endocr. Rev. (1998) 19:55–79.
   PubMed Web of Science ®Google Scholar
• GRUMBACH MM, AUCHUS RJ: Estrogen: consequencesand implications of human mutations in synthesis and action. J. Gun. Endocrinol. Metab. (1999) 84:4677–4694.
   PubMed Web of Science ®Google Scholar
• VAYSSIERE BM, DUPONT S, CHOQUART A et al.: Synthetic glucocorticoids that dissociate transactiva-tion and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol (1997) 11:1245–1255.
   PubMed Web of Science ®Google Scholar
• A novel glucocorticoid pharmacophore. Exp. Opin.Ther. Patents (2000) 10:117–120.
   Google Scholar
• BUJALSKA IJ, KUMAR S, STEWART PM: Does centralobesity reflect 'Cushing's disease of the omentum'? Lancet (1997) 349:1210–1213.
   PubMed Web of Science ®Google Scholar
• KOTELEVSEV Y, HOLMES MC, BURCHELL A et al.: 116-hydroxysteroid dehydrogenase Type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA (1997) 94:14924–14929.
   PubMed Web of Science ®Google Scholar
• COOPER MS, HEWISON M, STEWART PM: Glucocorticoidactivity, inactivity and the osteoblast. J. Endocrinol (1999) 163:159–164.
   PubMed Web of Science ®Google Scholar
• MUNDY G, GARRETT R, HARRIS S et al.: Stimulation of formation in vitro and in rodents by statins. Science (1999) 286:1946–1949.
   PubMed Web of Science ®Google Scholar
• •First description of the effects of statins on bone formation.
   Google Scholar
• DUCY P, AMLING M, TAKEDA S et al.: Leptin inhibits formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 100:197–207.
   PubMed Web of Science ®Google Scholar